Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream in participants with Hidradenitis Suppurativa. This is a randomized 16-week double-blind, vehicle-controlled (DBVC) study followed by a 16 week open label extension period (OLE) with an active treatment for participants who complete the DBVC period.
Epistemonikos ID: 9373e6903dee7ead1a7f5f3d98c5804cceab4c46
First added on: May 14, 2024